Evidence map›Paper›PMID 38560498›Full record

ReviewGenes & diseases2024

The roles and mechanisms of SREBP1 in cancer development and drug response.

Ying He, Shasha Qi, Lu Chen, Jinyu Zhu, Linda Liang, Xudong Chen, Hao Zhang, Lvjia Zhuo, Shujuan Zhao, Shuiping Liu and 1 more

Open access · diamondAbstract readReview
In one paragraph

Review in Genes & diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Ying HeSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Shasha QiSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Lu ChenSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Jinyu ZhuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Linda LiangSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Xudong ChenSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Hao ZhangSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Lvjia ZhuoSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Shujuan ZhaoSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Shuiping LiuSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Tian XieSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Hangzhou Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer occurrence and development are closely related to increased lipid production and glucose consumption. Lipids are the basic component of the cell membrane and play a significant role in cancer cell processes such as cell-to-cell recognition, signal transduction, and energy supply, which are vital for cancer cell rapid proliferation, invasion, and metastasis. Sterol regulatory element-binding transcription factor 1 (SREBP1) is a key transcription factor regulating the expression of genes related to cholesterol biosynthesis, lipid homeostasis, and fatty acid synthesis. In addition, SREBP1 and its upstream or downstream target genes are implicated in various metabolic diseases, particularly cancer. However, no review of SREBP1 in cancer biology has yet been published. Herein, we summarized the roles and mechanisms of SREBP1 biological processes in cancer cells, including SREBP1 modification, lipid metabolism and reprogramming, glucose and mitochondrial metabolism, immunity, and tumor microenvironment, epithelial-mesenchymal transition, cell cycle, apoptosis, and ferroptosis. Additionally, we discussed the potential role of SREBP1 in cancer prognosis, drug response such as drug sensitivity to chemotherapy and radiotherapy, and the potential drugs targeting SREBP1 and its corresponding pathway, elucidating the potential clinical application based on SREBP1 and its corresponding signal pathway.

Indexed as

CancerDrugLipid metabolism reprogrammingResistanceSREBP1

Identifiers

PMID38560498
PMCPMC10978545
OpenAlexW4381684738

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.